Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
Highlights
The global Overactive Bladder (OAB) Therapeutics market was valued at US$ 5100 million in 2022 and is anticipated to reach US$ 6042.2 million by 2029, witnessing a CAGR of 2.4% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Overactive Bladder (OAB) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Overactive Bladder (OAB) Therapeutics.
The Overactive Bladder (OAB) Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Overactive Bladder (OAB) Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Overactive Bladder (OAB) Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Overactive Bladder (OAB) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Overactive Bladder (OAB) Therapeutics 麻豆原创 Overview
1.1 Product Overview and Scope of Overactive Bladder (OAB) Therapeutics
1.2 Overactive Bladder (OAB) Therapeutics Segment by Type
1.2.1 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Anticholinergic Agents
1.2.3 Beta-3 Adrenoreceptor Agonists
1.3 Overactive Bladder (OAB) Therapeutics Segment by Application
1.3.1 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Value by Application: (2023-2029)
1.3.2 Hosptial
1.3.3 Clinci
1.3.4 Other
1.4 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2018-2029
1.4.2 Global Overactive Bladder (OAB) Therapeutics Sales 2018-2029
1.4.3 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Overactive Bladder (OAB) Therapeutics 麻豆原创 Competition by Manufacturers
2.1 Global Overactive Bladder (OAB) Therapeutics Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Overactive Bladder (OAB) Therapeutics Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Overactive Bladder (OAB) Therapeutics Average Price by Manufacturers (2018-2023)
2.4 Global Overactive Bladder (OAB) Therapeutics Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Overactive Bladder (OAB) Therapeutics, Product Type & Application
2.7 Overactive Bladder (OAB) Therapeutics 麻豆原创 Competitive Situation and Trends
2.7.1 Overactive Bladder (OAB) Therapeutics 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Overactive Bladder (OAB) Therapeutics Players 麻豆原创 Share by Revenue
2.7.3 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Overactive Bladder (OAB) Therapeutics Retrospective 麻豆原创 Scenario by Region
3.1 Global Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Overactive Bladder (OAB) Therapeutics Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2018-2029
3.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2018-2023
3.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2024-2029
3.3 Global Overactive Bladder (OAB) Therapeutics Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2018-2029
3.3.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2018-2023
3.3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2024-2029
3.4 North America Overactive Bladder (OAB) Therapeutics 麻豆原创 Facts & Figures by Country
3.4.1 North America Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2018-2029)
3.4.3 North America Overactive Bladder (OAB) Therapeutics Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Overactive Bladder (OAB) Therapeutics 麻豆原创 Facts & Figures by Country
3.5.1 Europe Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2018-2029)
3.5.3 Europe Overactive Bladder (OAB) Therapeutics Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Overactive Bladder (OAB) Therapeutics 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Country (2018-2029)
3.6.3 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Overactive Bladder (OAB) Therapeutics 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Overactive Bladder (OAB) Therapeutics Sales by Country (2018-2029)
3.7.3 Latin America Overactive Bladder (OAB) Therapeutics Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Overactive Bladder (OAB) Therapeutics 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Country (2018-2029)
3.8.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2018-2029)
4.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2018-2023)
4.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2024-2029)
4.1.3 Global Overactive Bladder (OAB) Therapeutics Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2018-2029)
4.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2018-2023)
4.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2024-2029)
4.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Overactive Bladder (OAB) Therapeutics Price by Type (2018-2029)
5 Segment by Application
5.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2018-2029)
5.1.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2018-2023)
5.1.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2024-2029)
5.1.3 Global Overactive Bladder (OAB) Therapeutics Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2018-2029)
5.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2018-2023)
5.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2024-2029)
5.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Overactive Bladder (OAB) Therapeutics Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Allergan
6.1.1 Allergan Corporation Information
6.1.2 Allergan Description and Business Overview
6.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
6.1.5 Allergan Recent Developments/Updates
6.2 Astellas Pharma
6.2.1 Astellas Pharma Corporation Information
6.2.2 Astellas Pharma Description and Business Overview
6.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
6.2.5 Astellas Pharma Recent Developments/Updates
6.3 Hisamitsu Pharmaceutical
6.3.1 Hisamitsu Pharmaceutical Corporation Information
6.3.2 Hisamitsu Pharmaceutical Description and Business Overview
6.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.3.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Ferring
6.5.1 Ferring Corporation Information
6.5.2 Ferring Description and Business Overview
6.5.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
6.5.5 Ferring Recent Developments/Updates
6.6 GlaxoSmithKline
6.6.1 GlaxoSmithKline Corporation Information
6.6.2 GlaxoSmithKline Description and Business Overview
6.6.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
6.6.5 GlaxoSmithKline Recent Developments/Updates
6.7 Ion Channel Innovations
6.6.1 Ion Channel Innovations Corporation Information
6.6.2 Ion Channel Innovations Description and Business Overview
6.6.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
6.7.5 Ion Channel Innovations Recent Developments/Updates
6.8 Kwang Dong Pharmaceutical
6.8.1 Kwang Dong Pharmaceutical Corporation Information
6.8.2 Kwang Dong Pharmaceutical Description and Business Overview
6.8.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.8.5 Kwang Dong Pharmaceutical Recent Developments/Updates
6.9 Lanzhou Institute of Biological Products
6.9.1 Lanzhou Institute of Biological Products Corporation Information
6.9.2 Lanzhou Institute of Biological Products Description and Business Overview
6.9.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
6.9.5 Lanzhou Institute of Biological Products Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 ONO Pharmaceutical
6.11.1 ONO Pharmaceutical Corporation Information
6.11.2 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.11.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.11.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
6.11.5 ONO Pharmaceutical Recent Developments/Updates
6.12 Sanofi
6.12.1 Sanofi Corporation Information
6.12.2 Sanofi Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.12.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
6.12.5 Sanofi Recent Developments/Updates
6.13 Tengion
6.13.1 Tengion Corporation Information
6.13.2 Tengion Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.13.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
6.13.5 Tengion Recent Developments/Updates
6.14 Teva Pharmaceutical Industries
6.14.1 Teva Pharmaceutical Industries Corporation Information
6.14.2 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Description and Business Overview
6.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
6.14.5 Teva Pharmaceutical Industries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Overactive Bladder (OAB) Therapeutics Industry Chain Analysis
7.2 Overactive Bladder (OAB) Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Overactive Bladder (OAB) Therapeutics Production Mode & Process
7.4 Overactive Bladder (OAB) Therapeutics Sales and 麻豆原创ing
7.4.1 Overactive Bladder (OAB) Therapeutics Sales Channels
7.4.2 Overactive Bladder (OAB) Therapeutics Distributors
7.5 Overactive Bladder (OAB) Therapeutics Customers
8 Overactive Bladder (OAB) Therapeutics 麻豆原创 Dynamics
8.1 Overactive Bladder (OAB) Therapeutics Industry Trends
8.2 Overactive Bladder (OAB) Therapeutics 麻豆原创 Drivers
8.3 Overactive Bladder (OAB) Therapeutics 麻豆原创 Challenges
8.4 Overactive Bladder (OAB) Therapeutics 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
听
听
*If Applicable.